Differentially regulated by inhibitors of methylation and histone deacetylation in lung cancer and melanoma cells without physical epigenetic alterations in its promoter. MIG-6 may serve as valuable biomarkers for determining the sensitivity/suitability of a cancer type for treatment with DNMT and/or HDAC inhibitors in the 84573-16-0 clinic. Protein C inhibitor is a serine protease inhibitor and a member of the serpin superfamily. PCI has originally been described as a 1494675-86-3 plasma inhibitor of activated protein C. Later, the inhibition of several other proteases, including the pancreatic enzymes trypsin and chymotrypsin, by PCI has been shown.. Like other members of the serpin family, PCI acts as a suicide substrate for its target proteases. Serpins have an exposed reactive center loop which offers a potential cleavage site for the protease. The protease recognizes this sequence and binds to the serpin, forming a reversible Michaelis- like complex. Then the protease cleaves the reactive site peptide bond and the serpin incorporates the RCL into b-sheet A, producing a covalent serpin-protease complex. The enzymeinhibitor complex can dissociate, leaving behind an active protease and a cleaved, inactive serpin. Heparin and other glycosaminoglycans can modify the activity and target enzyme specificity of PCI. The heparin-binding site is a basic patch on helix H, which lies close to the reactive center loop. Heparin changes the charge of this area, thereby modifying the affinity of PCI towards different proteases. Heparin stimulates the inhibition of APC and thrombin, but abolishes the inhibition of tissue kallikrein by PCI. Antithrombin, another heparin-binding serpin, uses a different mechanism. Both low molecular weight and unfractionated heparin bind to helix D. This binding leads to a conformational change of AT and an additional part of the reactive center loop is exposed. This results in increased inhibition of coagulation proteases. UFH is furthermore big enough to span from helix D to the protease. It thereby forms a template for AT and thrombin and enhances their interaction. By Northern blotting, a wide tissue distribution of PCI has been demonstrated in humans. PCI mRNA is present in the liver, kidney, heart, brain, lung, spleen, reproductive system and pancreas
